Overview

  • Product name

    Anti-CCR5 antibody [T21/8]
    See all CCR5 primary antibodies
  • Description

    Mouse monoclonal [T21/8] to CCR5
  • Host species

    Mouse
  • Tested applications

    Suitable for: WB, IP, ELISA, IHC-P, Flow Cytmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Human CCR5

  • Positive control

    • Human tonsil tissue. Normal Human peripheral blood cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab110103 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Predicted molecular weight: 41 kDa.
IP Use at an assay dependent concentration.
ELISA Use at an assay dependent concentration.
IHC-P Use a concentration of 20 µg/ml.
Flow Cyt Use 0.5µg for 105-8 cells.

in a final volume of 100 ul.

 

 

 

ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

 

Target

  • Function

    Receptor for a number of inflammatory CC-chemokines including MIP-1-alpha, MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 R5 isolates.
  • Tissue specificity

    Highly expressed in spleen, thymus, in the myeloid cell line THP-1, in the promyeloblastic cell line KG-1A and on CD4+ and CD8+ T-cells. Medium levels in peripheral blood leukocytes and in small intestine. Low levels in ovary and lung.
  • Involvement in disease

    Genetic variation in CCR5 is associated with suseptibility to diabetes mellitus insulin-dependent type 22 (IDDM22) [MIM:612522]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
  • Sequence similarities

    Belongs to the G-protein coupled receptor 1 family.
  • Post-translational
    modifications

    Sulfated on at least 2 of the N-terminal tyrosines. Sulfation contributes to the efficiency of HIV-1 entry and is required for efficient binding of the chemokines, CCL3 and CCL4.
    O-glycosylated, but not N-glycosylated. Ser-6 appears to be the major site. Also sialylated glycans present which contribute to chemokine binding. Thr-16 and Ser-17 may also be glycosylated and, if so, with small moieties such as a T-antigen.
    Palmitoylation in the C-terminal is important for cell surface expression, and to a lesser extent, for HIV entry.
    Phosphorylation on serine residues in the C-terminal is stimulated by binding CC chemokines especially by APO-RANTES.
  • Cellular localization

    Cell membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • AM4 7 antibody
    • C C chemokine receptor type 5 antibody
    • C C CKR 5 antibody
    • C-C chemokine receptor type 5 antibody
    • C-C CKR-5 antibody
    • C-C motif chemokine receptor 5 A159A antibody
    • CC Chemokine Receptor 5 antibody
    • CC Chemokine Receptor Type 5 antibody
    • CC CKR 5 antibody
    • CC-CKR-5 antibody
    • CCCKR 5 antibody
    • CCCKR5 antibody
    • CCR 5 antibody
    • CCR-5 antibody
    • CCR5 antibody
    • CCR5 chemokine (C C motif) receptor 5 antibody
    • CCR5_HUMAN antibody
    • CD 195 antibody
    • CD195 antibody
    • CD195 Antigen antibody
    • Chemokine C C motif receptor 5 antibody
    • Chemokine receptor CCR5 antibody
    • CHEMR13 antibody
    • CKR 5 antibody
    • CKR5 antibody
    • CMKBR 5 antibody
    • CMKBR5 antibody
    • FLJ78003 antibody
    • HIV 1 Fusion Coreceptor antibody
    • HIV-1 fusion coreceptor antibody
    • HIV1 fusion coreceptor antibody
    • IDDM22 antibody
    • MIP-1 alpha receptor antibody
    see all

Images

  • ab110103 at 20µg/ml staining CCR5 in formalin-fixed, paraffin-embedded Human tonsil tissue.
  • Staining of normal Human peripheral blood cells with 0.25µg of purified mouse IgG1, K isotype control (open histogram) or 0.25 µg of ab110103 (colored histogram), followed by biotin Anti-mMouse IgG and SAv-PE.
    Cells in the lymphocyte gate were used for analysis.

References

This product has been referenced in:

  • Huang R  et al. Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells. Oncol Lett 13:3379-3386 (2017). Read more (PubMed: 28521443) »
See 1 Publication for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A

Answer


The anti-CCR5 antibody ab110103 was used in IHC-P as followed :

Antigen retrieval: Steam slides in 0.01 M sodium citrate buffer, pH 6.0 at 99-100°C - 20 minutes
Primary incubation: diluted primary antibody (20 µg/ml), 45 minutes at room temperature

Read More

Answer

Thank you for your inquiry. Unfortunately, I cannot recommend any of these antibodies to your customer. The immunogen for these antibodies was the full-length CCR5 protein. We can suggest that all of them will recognize an epitope in the extracellular domains since they are all suitable for flow cytometry without the need to fix and permeabilise the cells. But to my knowledge the epitopes have not been mapped and we do not know if they bind to the n-terminal part of CCR5. I am sorry I could not provide you and your customer with a positive answer on this occasion. Please do not hesitate to contact me with any further questions.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up